Navigation Links
ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
Date:4/1/2008

with a simultaneous webcast on April 1 at 4:30 PM Eastern Time to discuss today's announcement. To access the live conference call, U.S. and Canadian participants may dial 866-713-8566; international participants may dial 617-597-5325. The access code for the live call is 78744677. To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the replay is 32464807. This conference call will also be webcast live and archived on ISTA's website for 30 days at http://www.istavision.com.

Xibrom(TM) (bromfenac ophthalmic solution)

Xibrom is a topical non-steroidal anti-inflammatory compound for the treatment of ocular inflammation and pain. Xibrom, approved in 2005, is the first and only FDA-approved twice-daily NSAID for inflammation and reduction of pain following cataract surgery. Xibrom is the fastest growing ophthalmic product in 2007, according to IMS data. Xibrom, under a different trade name but identical formulation, was launched in Japan in 2000 by Senju Pharmaceuticals Co. Ltd. ISTA acquired U.S. marketing rights for Xibrom in 2002 and launched the product in the U.S. in 2005.

ABOUT ISTA PHARMACEUTICALS

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at '/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
3. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
4. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
7. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
8. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
9. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
10. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
11. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  PENTAX Medical, a healthcare industry leader ... leader in ultrasound imaging, recently announced renewed collaborative ... further innovation in the development of Endoscopic Ultrasound ... and PENTAX Medical endoscopic portfolio have formed one ... systems. This agreement will continue to grow their ...
(Date:5/17/2013)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( ... announced today that the United States Food and Drug ... application(IND) for ORMD-0801, its oral insulin capsule. ... to proceed," stated Nadav Kidron , ... milestone for Oramed and we look forward to continuing ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... and Research (A*STAR) and Switzerland,s Cytos ... been dosed in a Phase 1 clinical trial with their ... virus-like particle (VLP) technology. In this first Phase 1 clinical ... and its potential to protect against H1N1 influenza infection will ...
Breaking Medicine Technology:PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
... with Two Abstracts Accepted for ... November 2008, BRIDGEWATER, N.J., Sept. 4 ... the treatment of,cardiovascular and metabolic disease, today announced ... Company,s board of directors., Peter Garrambone,s career ...
... Group (NYSE: SCR ), a leading manufacturer ... the patented,anti-cancer biotech product Endu (also known as ... Phase IV clinical study., At the request ... clinical study,to further validate the safety and therapeutic ...
Cached Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3
(Date:5/19/2013)... (PRWEB) May 19, 2013 Passages Malibu, ... treatment center, has announced this week the launch of ... the brands’ social media channels. “We are always ... treatment community and to get feedback regarding sobriety, what’s ... CEO and co-founder of the Passages Addiction Treatment ...
(Date:5/19/2013)... Argentina: Yoga classes ( clases de Yoga ) will ... Sivananda Yoga Vedanta Center. The center is located ... are 90 minutes and are offered all week long. ... environment, allowing visitors to enjoy the benefits of Yoga, ... , The Yoga classes follow the following principles: , ...
(Date:5/19/2013)... Ponte Vedra Beach, Florida (PRWEB) May 19, 2013 ... healthcare value and market access, is pleased to unveil ... online trade show environment that provides a powerful array ... solutions to partners in the US and abroad. , ... technology, and will offer attendees the look and feel ...
(Date:5/19/2013)... The legal team at Pulaski & ... concerted effort to connect women and families coping with ... Yaz, Yasmin & Ocella with the legal representation they ... the notorious birth control drugs as well as news ... Yaz, Yasmin & Ocella were very popular birth control ...
(Date:5/18/2013)... Cambridge House of Maryville , a BMA ... area, is hosting a Memorial Day Weekend Barbecue from 11 ... community, which is located at 6960 State Rte. 162 in ... on Medicaid, who need some help to maintain their independence. ... by homemade ice cream for dessert,” says Tracy Skaer-Henry, Administrator ...
Breaking Medicine News(10 mins):Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Metro East Affordable Assisted Living Community to Host Memorial Day Weekend Barbecue 2
... risk of breast cancer, most young women who were treated ... appropriate mammography screening, according to a study in the January ... chest radiation for a pediatric malignancy face a significantly increased ... of breast cancer begins to increase as early as 8 ...
... alternating cycles of chemotherapy and radiation have similar outcomes ... to data from a randomized controlled trial in the ... the National Cancer Institute. , Previous trials in ... followed by radiation was as effective as total removal ...
... Papillary Thyroid Cancer ,A germ-line mutation in the ... with multi-nodular goiter (MNG) and with progression to papillary thyroid ... have MNG progress to PTC, but a genetic link between ... to be involved in thyroid development and is expressed at ...
... HAMILTON, BERMUDA, Jan. 27 Warner Chilcott Limited (Nasdaq: ... year 2009 results.Total revenues for 2009 are expected to be ... results primarily being driven by LOESTRIN 24 FE, DORYX, and ... is anticipated to be in the range of 79% to ...
... to Protect World,s Supply of Donated Blood ... Continued Expansion into New Global Markets and ... PANTHER Instrument- Companies Also Plan Exploratory Collaboration ... Guidance Including Additional Revenue and Profit from ...
... Holmes (Amex: HH ) today announced the ... General Counsel and Corporate Secretary. He has also ... Rosenblum has over 23 years of corporate legal experience ... contract, consumer and other class actions, as well as ...
Cached Medicine News:Health News:Many women who survived childhood cancer do not undergo recommended breast cancer screening 2Health News:Sequential and alternating chemotherapy and radiation equally effective in larynx cancer therapy 2Health News:Also in the Jan. 27 JNCI 2Health News:Also in the Jan. 27 JNCI 3Health News:Also in the Jan. 27 JNCI 4Health News:Warner Chilcott Announces 2009 Financial Guidance 2Health News:Warner Chilcott Announces 2009 Financial Guidance 3Health News:Warner Chilcott Announces 2009 Financial Guidance 4Health News:Warner Chilcott Announces 2009 Financial Guidance 5Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 2Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 3Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 4Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 5Health News:Hooper Holmes Names Mark Rosenblum Senior Vice President, General Counsel and Corporate Secretary 2Health News:Hooper Holmes Names Mark Rosenblum Senior Vice President, General Counsel and Corporate Secretary 3
... reliable strength for temporary wound support. ... compliant and stretchable support material is ... is not required. Predictable absorption. Polyglactin ... inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... designed for the repair of abdominal hernias. ... has two distinct sides. One side ... layer of sodium hyaluronate and carboxymethylcellulose (similar ... coated side is bioresorbable, providing a temporary ...
... Human explant studies have confirmed Atriums ... maximum clinical performance in hernia repair. ... thinner and less dense hernia mesh ... rigid repair. Since 1994, when Atrium ...
Medicine Products: